N

Nabla Bio pricing

The partnering page routes to a business development mailbox rather than to commercial terms. Deal announcements give more than $550 million in combined upfront and milestone payments plus royalties across the AstraZeneca, Bristol Myers Squibb and Takeda collaborations of May 2024, and double digit millions in upfront and research cost payments against success based payments that may exceed $1 billion on the second Takeda agreement of October 2025. The company describes itself as revenue generating and publishes no revenue figure or rate card.

Pricing terms

How Nabla Bio pricing works

Pricing model
Negotiated collaboration. Revenue comes from multi year biologics discovery agreements with pharmaceutical partners, paid through an upfront payment, milestone payments as programs progress, and royalties on any approved product. No software license, subscription or platform access is offered.
Implementation
Nabla delivers designs rather than installing, licensing or configuring software, so there is no implementation event to charge for. It runs its own wet lab and carries the cost of testing designs before they reach a partner, and partners carry development and commercialization on their side.
Compared on price

Nabla Bio pricing against its alternatives

Published prices for Nabla Bio and the products closest to it. Each figure is as the vendor publishes it, in its own currency and billing unit.

All Nabla Bio alternatives →

Questions

Nabla Bio pricing, answered

How much does Nabla Bio cost?

Nabla Bio does not publish a price. The partnering page routes to a business development mailbox rather than to commercial terms.

Does Nabla Bio charge an implementation fee?

Nabla delivers designs rather than installing, licensing or configuring software, so there is no implementation event to charge for. It runs its own wet lab and carries the cost of testing designs before they reach a partner, and partners carry development and commercialization on their side.